Please assess the completion status of the following clinical trial:

Trial Title: HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of initial or recurrent anal or vulvar high-grade squamous intraepithelial lesion (AIN2/3 or VIN2/3) diagnosed on or after 1/1/2014; study pathologist will use p16 staining as needed to rule out low-grade squamous intraepithelial lesion (LSIL) disease~* \>= 2 months since last therapy for HSIL~* No clinical evidence of HSIL on screening examination; if HSIL is suspected, a biopsy will be done to exclude HSIL; patients whose screening visit reveals HSIL on biopsy, may be re-screened \>= 2 months after therapy~* Resident in the catchment area of the clinics and willing to attend up to 8 clinic visits for a 36-month period~* Sexually active women of child-bearing potential must be willing to use effective contraception through month 7 of the study~* If human immunodeficiency virus (HIV) positive, receipt of anti-retroviral therapy continuously for at least 6 months prior to enrollment~* Ability to give informed consent~* Willingness to sign medical records release form and tissue release form~Exclusion Criteria:~* Currently pregnant~* Chemotherapy (current, within the last month, or anticipated in the next 7 months)~* Prior history of invasive HPV-related anogenital cancer (cervical, vaginal, vulvar, penile, or anal cancer), or oropharyngeal cancer (base of tongue, tonsil); prior cancer at other sites (including most of oral cavity) or larynx are not exclusions~* Unstable medical condition (e.g., another malignancy requiring treatment, malignant hypertension, poorly controlled diabetes, another cancer except for fully excised non-melanoma skin cancer)~* Prior HPV vaccination~* Known allergy or intolerance to lidocaine~* Currently participating in an interventional research study related to HPV, except the Anal Cancer HSIL Outcomes Research (ANCHOR) study (NCT02135419)~* Any other condition which, in the opinion of the investigator, may compromise the subject's ability to follow study procedures and safely complete the study

- Gender: ALL
- Minimum Age: 27 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (recombinant human papillomavirus nonavalent vaccine) (Type: EXPERIMENTAL): Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline, 2 months, and 6 months.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive placebo IM at baseline, 2 months, and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).